GDmounjaro vs Semaglutide UK: What the Research Actually Shows

Semaglutide dominated the weight loss conversation for three years. Ozempic. Wegovy. The drug everyone was talking about. Then GDmounjaro (tirzepatide) arrived and the head-to-head data changed the picture significantly. This article covers what the research actually shows, without the marketing.

How They Work — The Key Difference

Both compounds target GLP-1 receptors — the receptors that control appetite, gastric emptying and insulin response. Semaglutide hits GLP-1 only. GDmounjaro hits GLP-1 and GIP simultaneously.

GIP (glucose-dependent insulinotropic polypeptide) is a separate hormone that also plays a role in appetite regulation and fat metabolism. When you activate both pathways at once, the combined effect on appetite suppression and metabolic rate is greater than either alone. That's the mechanism behind the difference in results.

The SURMOUNT-5 Trial: Head-to-Head Data

The most important comparison came from the SURMOUNT-5 trial, which put tirzepatide directly against semaglutide in people with obesity but without diabetes. The results showed that tirzepatide produced approximately 47% greater weight loss than semaglutide over the trial period.

That is not a marginal difference. A 47% advantage in the primary outcome of a head-to-head trial is substantial. In absolute terms, participants on the maximum tirzepatide dose lost around 20% of body weight compared to roughly 14% on maximum semaglutide.

Phase 3 Trial Results: Both Compounds

Semaglutide (STEP trials): Average weight loss of 14.9% of body weight at 68 weeks on 2.4mg weekly. Significant and well-documented. The largest weight loss seen from any approved medication at the time of its approval.

GDmounjaro (SURMOUNT trials): Average weight loss of 20.9% of body weight at 72 weeks on the 15mg dose. In the highest-dose cohort, some participants lost over 25% of body weight. These were the largest weight loss results ever seen in a pharmaceutical trial for obesity at the time of publication.

Side Effect Profiles

Both compounds share similar side effect profiles because they share the GLP-1 mechanism. Nausea, vomiting and gastrointestinal discomfort are the most common, particularly at dose initiation. Both are typically started at low doses and titrated upward to allow the body to adapt.

GDmounjaro does not appear to produce meaningfully more gastrointestinal side effects than semaglutide despite the additional GIP mechanism. The SURMOUNT-5 trial reported comparable discontinuation rates between the two compounds.

Regulatory Status in the UK

Both tirzepatide and semaglutide are approved medicines in the UK. Tirzepatide is approved as Mounjaro for type 2 diabetes and weight management. Semaglutide is approved as Ozempic (diabetes) and Wegovy (weight management). Both require a prescription from a qualified clinician.

G&D Pharma supplies tirzepatide as GDmounjaro for research purposes only. This is not an approved route for treating any medical condition.

Which Is More Effective?

Based on available research, tirzepatide produces greater weight loss than semaglutide at maximum approved doses. The SURMOUNT-5 head-to-head trial confirmed this with a 47% advantage in weight loss outcomes. The dual GIP/GLP-1 mechanism is the likely explanation — hitting two independent appetite-regulating pathways produces a synergistic effect.

Both compounds are significantly more effective than older weight loss medications. The question of which is right for any individual is one for a qualified clinician, not a research article.